Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort for Covid-19
NCT04331054Phase 3Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2020
- Primary completion
- May 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Time to clinical improvement at 30 days. Started Apr 2020; status: terminated.
02
Drugs
budesonide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04331054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04331054.